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ABSTRACT 
Sustained release formulations have been extensively studied for their benefits in improving various physicochemical and pharmacokinetic 
properties of large number of drugs. The aim of this study was to develop and evaluate sustained release capsules of losartan potassium in order 
to provide drug release over a long period of time. This allows the drug much time for absorption in gastrointestinal tract (GIT) and hence may 
increase the bioavailability of the drug. Carbopol 971 P was used as rate controlling polymer for the preparation of capsules. The capsules were 
evaluated for matrix integrity and drug release using USP type II dissolution apparatus. The sustained release capsules showed excellent matrix 
integrity and released more than 90% of the drug over a period of 12 hours. The kinetic studies showed that the drug release from the carbopol 
matrices followed Korsmeyer Peppas release kinetics and hence the mechanism of drug release was a combination of more than one processes 
i.e. diffusion and erossion. Hydration volume as well as matrix integrity were affected by the change in the amount of the polymer in the 
capsules. The study suggests that carbopol 971P capsules can be efficiently used to control and extend the release of losartan potassium over a 
long period. Thus improved absorption and bioavailability can be achieved which requires further studies in animals in future. 
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INTRODUCTION 
Drug release characteristics of a dosage form are very 
important in determining the extent of the drug reaching the 
blood and the actual site of action. Depending upon the 
physicochemical properties of a drug, its absorption in 
different regions of the gastrointestinal tract varies 1. This in 
many cases results in incomplete absorption and low 
bioavailability of the drug. A large number of approaches 
have been adopted to improve the physicochemical and 
pharmacokinetic properties of many drugs e.g. using salt 
form of drug increases drug solubility 2, 3 or inclusion 
complexes 4-6. Also, a prodrug may be more permeable via 
biological membranes than the actual drug e.g. levodopa 
(prodrug) is more permeable than the original drug 
(dopamine) 7. After crossing the blood brain barrier 
levodopa gets converted to dopamine which is the actual 
drug that shows action. Similarly, solid dispersions 8, 9 and 
nano drug delivery systems are used to improve solubility 
and bioavailability of many drugs 10, 11. 
Another approach that is used to increase the absorption and 
bioavailability of the drugs is the development of sustained 
release dosage forms 12-14. Sustained release dosage forms 
provide drug release at relatively slower rate than 
conventional dosage forms. The drug is released in smaller 
amounts giving enough time to the drug to absorb. This is 
beneficial in case of drugs that are absorbed by saturable 
mechanism in which case the release of large amounts of 
drug near the absorption site saturates absorption 
mechanism 15, 16. Drugs that are highly soluble are released in 
large amounts and hence saturate the pathway involved in 
drug absorption. While low solubility drugs are inherently 
sustained release in nature, release of highly soluble drugs 
are required to be controlled.  This can provide enough time 
for the drug to absorb. 
Carbopol polymers have been extensively used in sustained 
release formulations 17-19. The polymeric chains in carbopol 
are chemically crosslinked that provide the rate controlling 
properties to the polymer. The polymer is available in 
number of grades (Carbopol 974P, 934P, 940P, 70G etc.) 
differing in the extent of crosslinking. The polymer 
undergoes rapid hydration when placed in an aqueous 
medium. Upon hydration the polymer chains form gel like 
structures that cause enormous swelling of the polymer. The 
chemical crosslinking between the polymeric chains imparts 
the mechanical strength to the capsules and more 
Wani et al                                                                                                                     Journal of Drug Delivery & Therapeutics. 2019; 9(2-s):92-97 
ISSN: 2250-1177                                                                                  [93]                                                                                 CODEN (USA): JDDTAO 
importantly is key in retarding the rate of drug release from 
the capsules. Carbopol 971 P has been used to develop 
sustained release products of a number of drugs. 
Losartan potassium is an angiotensin II receptor blocker that 
is used primarily for the treatment of hypertension 20. The 
oral dose of losartan potassium for the treatment of 
hypertension is 25, 50 and 100 mg. Due to extensive first 
pass metabolism the oral bioavailability of the drug is only 
25-33% 21. It is suggested that the use of sustained release 
formulations of losartan potassium may increase the 
bioavailability of the drug. 
MATERIALS AND METHODS 
Losartan potassium was obtained Eaton Laboratories, 
Srinagar J&K, as a gift sample. Carbopol 971 P was a 
generous gift from Lubrizol. All the other chemicals were of 
analytical grade. 
Preparation of Sustained Release Capsules 
Sustained release capsules of losartan potassium were 
prepared by simply mixing all the ingredients and then 
manually filling the mixture into hard gelatin capsules in 
proper amounts. Carbopol and losartan potassium were 
mixed in different ratios in order to evaluate the effect of 
carbopol on drug release. The mixing was carried out for 10-
15 min. The amount of carbopol was tuned to get the 
maximum amount of drug release over the period of 12 
hours without losing the matrix integrity. The composition of 
various formulations prepared is shown in table 1. 
 
Table 1: Composition of various sustained release carbopol formulations 
Formulation Polymer Drug Capsule wt. 
F1 200 50 250 
F2 175 50 225 
F3 150 50 200 
F4 125 50 175 
F5 100 50 150 
F6 75 50 125 
F7 50 50 100 
 
Weight Variation 
Weight variation of the capsules was determined by 
calculating the average weight of 20 capsules using an 
electronic balance and then determining the average 
deviation of each capsule from the average. 
Content Uniformity 
Contents of 10 capsules were dissolved in 0.1 N HCl and the 
solution obtained was filtered through Whatman filter paper. 
Drug content in the filtered solution was detected by 
measuring the absorbance of the filtrate by UV 
spectrophotometer at λmax 254 nm 22. 
Polymer Hydration 
Hydration and swelling studies were done to determine the 
amount of water intake by the carbopol capsules upon 
immersion into an aqueous medium. The experiment was 
carried out in USP type II dissolution apparatus. The 
capsules were placed in 900 ml of 0.1 N HCl for 12 hours and 
taken at regular time intervals for measuring the dimensions 
of the capsules using a Vernier caliper. 
Drug Release Studies 
Drug release studies were carried out in USP type II 
dissolution apparatus. The drug containing capsules were 
placed in the dissolution flasks containing 900 ml of 0.1 N 
HCl as dissolution medium maintained at a temperature of 
37± 0.5 ºC. The dissolution medium was stirred a constant 
speed of 100 rpm throughout the experiment. The duration 
of the experiment was 12 hours. 5ml samples were taken 
after every hour and after proper dilution absorbance of 
each sample was measured using at λmax 254 nm UV 
spectrophotometer. From the values of absorbances the 
percentage drug release at different time intervals was 
calculated. 
RESULTS AND DISCUSSION 
Preliminary Studies 
In order to choose a suitable polymer for developing 
sustained release capsules of losartan potassium various 
polymers were thoroughly screened. The screening was 
done on the basis of matrix integrity and the drug release 
from the capsules. On the basis of this evaluation Carbopol 
971 P was showed positive results and was hence chosen for 
thee further studies. 
Hydration Behaviour of Carbopol 971P Capsules 
Carbopol capsules were placed for 12 hours in 0.1 N HCl and 
examined for change in their volume. The capsules were 
taken out regularly and using a Vernier calliper the 
dimensions of the capsules were measured. It was observed 
that the volume of the carbopol capsules increased as the 
capsules spent more and more time in the dissolution 
medium (0.1N HCl). After 12 hours the capsules volume was 
almost double the initial volume of the capsules. Carbopol is 
a hydrophilic polymer that undergoes extensive hydration 
when placed in an aqueous medium 23. As the capsules are 
placed inside the dissolution medium the water penetrates 
into the bulk of the capsules and the individual polymeric 
chains get surrounded by tremendous amount water. The 
hydrated polymer chains form gel like structures increasing 
the bulk of each polymer chain. When hundreds of such 
polymer chains get hydrated it increases the overall volume 
of hydration of the capsules 24. 
Effect of Drug on Hydration Behaviour of Carbopol 
Capsules 
The addition of the drug had some effect on the hydration 
properties of the capsules. It was observed that the 
incorporation of the drug decreased the swelling behaviour 
of the capsules. Figure 1 shows the effect of addition of drug 
on the hydration behaviour of carbopol capsules. It was 
found that as the amount of the in the capsules increases the 
hydration volume decreases. This may be because of 
replacement of some amount of polymer by the drug leading 
to less gelation and hence decreased swelling. Also, since 
losartan potassium is a hydrophilic drug, as the water enters 
the capsule the drug gets dissolved and is released into the 
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medium decreasing the total content of the capsule and 
hence decreasing the hydration volume 23. 
 
Figure 1: Effect of Amount of drug on hydration behaviour of 
Carbopol 971P capsules. The hydration volume of the 
capsules decreases as the amount of the in the capsules 
increases 
Effect of Polymer:Drug Ratio Matrix Integrity of Capsules 
The capsules were placed in 900 ml of 0.1N HCl for 12 hours 
with at temperature 37± 0.5 ºC and stirred at 100 rpm and 
the time from which the capsules started showing the signs 
of erosion was noted.  
 
Figure 2 Effect of Carbopol 971P: Drug ratio on matrix 
integrity of capsules.  
The capsules were placed in 0.1N HCl for 12 hours with 
stirred at 100 rpm and temperature 37± 0.5 ºC and the 
matrix integrity was noted in terms of the time for which the 
capsules withstood the hydrodynamic force of the medium. 
Matrix integrity was reported in terms of the time for which 
the capsules withstood the hydrodynamic force of the 
medium. It was found that polymer from the capsules did not 
erode upto a certain limit of polymer:drug ratio, beyond 
which the capsules could not withstand the hydrodynamic 
force of the medium and the polymer started eroding faster 
as the polymer:drug ratio decreased (figure 2). 
Drug Release Studies 
As mentioned earlier, drug release studies were carried out 
in USP type II dissolution apparatus containing 900mll of 
0.1N HCl maintained at temperature 37± 0.5 ºC and stirred 
at a rate of 100 rpm. The carbopol matrices provided 
sustained drug release over the period of 12 hours. 
Formulations F1, F2, F3, F4 and F5 showed good matrix 
integrity while formulation F6 and F7 showed polymer 
abrasion from the surface of the capsules. This may be due to 
the fact that since the drug:polymer ratio was 1:1, the drug 
release from the capsules might have left large voids within 
the polymer matrix, hence loosening the gel structure and 
causing erosion 23, 25. Table 2 gives the 12 hour drug release 
data from the carbopol capsules. Carbopol capsules 
successfully retarded the drug release from its matrices and 
it was observed that as the proportion of the carbopol in the 
capsules was increased the amount of the drug release 
decreased as shown in figure 3. This may be attributed to the 
fact that polymeric chains in carbopol are tightly crosslinked 
that decreased the drug penetration into the carbopol matrix 
and hence not allowing drug release in large amounts 24, 26. 
 
Table 2: Percentage Cumulative drug release from sustained release carbopol capsules 
Time (hrs) F1  F2  F3  F4 F5  
1 11.53 12.87 15.45 17.88 19.59 
2 18.67 20.43 22.83 23.13 25.76 
3 22.96 23.69 26.97 27.87 33.23 
4 28.78 31.98 33.18 35.77 39.49 
5 34.11 37.54 39.07 41.24 47.64 
6 40.23 42.12 45.24 49.33 52.19 
7 46.55 48.32 52.56 56.12 59.38 
8 51.26 55.79 58.59 61.59 67.27 
9 58.79 60.11 64.36 67.09 76.54 
10 65.85 66.04 70.71 75.05 83.02 
11 69.19 73.68 77.52 82.48 88.13 
12 73.06 77.11 84.05 86.83 93.44 
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Figure 3: Comparison of drug release from different Carbopol 971P sustained release capsules containing different amounts of 
Carbopol 971P at different time points upto 12 hours. The drug release was evaluated using USP type II dissolution apparatus. 
 
Effect of Carbopol 971P on drug release from sustained 
release capsules 
Formulations containing different amounts of carbopol 971P 
were prepared and drug release studies were carried out in 
0.1 N HCl in USP type II dissolution apparatus. It was found 
that with increase in the amount of carbopol 971P in the 
capsules the amount of drug released at different time points 
over the period of 12 hours, decreased. Carbopol 971P is a 
chemically crosslinked polymer that undergoes rapid 
hydration in water to give rise to a 3D gelatinous structure.  
 
Figure 4: Effect of varying amounts of Carbopol 971P on drug 
release from the sustained release capsules. The graph 
shows the total amount of the drug released after 12 hours 
from capsules with different amounts of Carbopol971P. 
This provides high efficiency to the polymer in controlling 
the drug release rate from the formulation. As the amount of 
the polymer increases the number of gel structures formed 
may increase hence further decreasing the rate of drug 
release from the capsules 24, 26. Figure 4 shows the effect of 
carbopol 971P on the drug release from sustained release 
capsules. 
Drug Release Kinetics 
In order to determine the mechanism of drug release from 
the carbopol matrices drug dissolution modelling was 
applied to the drug release. It was found that the drug 
release followed Korseyer-Peppas model of release kinetics. 
The graph based on Korsmeyer-Peppas model showed R2 
value of 0.9978 which was found to be highest. The value of 
“n” was found to be 0.750 which falls between 0.45 and 0.89 
which demonstrates that the drug release was non-Fickian. 
Thus from the results it can be suggested that the drug from 
the carbopol 971P formulations was released by more than 
one mechanisms that may be a combination of diffusion and 
erosion mechanisms 27, 28. Figure 5 shows the various 
dissolution models applied to drug release data obtained 
from sustained release carbopol 971P capsules. Values of 
various parameters of dissolution data models are shown in 
table 3. 
 
 
Table 3: Various parameters obtained from the modelling treatment of dissolution data form the sustained release carbopol 
971P capsules 
Formulation Zero Order First Order Higuchi Korsmeyer-Peppas 
 K0 R2 K1 R2 KH R2 KKP N R2 
F1 6.471 0.9760 0.096 0.9753 18.531 0.8840 9.295 0.834 0.9951 
F2 6.792 0.9677 0.104 0.9734 19.489 0.8953 10.351 0.807 0.9951 
F3 7.271 0.9613 0.116 0.9600 20.881 0.8978 11.349 0.796 0.9923 
F4 7.665 0.9537 0.126 0.9556 22.039 0.9036 12.394 0.779 0.9915 
F5 8.375 0.9394 0.148 0.9451 24.134 0.9158 14.436 0.750 0.9916 
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Figure 5: Kinetic modelling applied to the dissolution data or drug release data of Carbopol971P sustained release capsules. a) 
Zero Order Release Model; b) First Order Release Model; c) Higuchi Model; d) Korsmeyer-Peppas Model 
 
Weight Variation 
20 capsules were tested in weight variation test. All the capsules were found to pass the test. Table 4 shows the details of the 
weight variation test. 
Table 4: Weight variation test conducted on sustained release carbopol 971P capsules 
Formulat
ion 
No. of capsules Amount of drug Capsule wt. 
(Experimental) 
Acceptable Wt. 
variation 
No. of capsules 
passed 
F1 20 250 mg 248-252 mg ±7.5% All 
F2 20 225 mg 221-229 mg ±7.5% All 
F3 20 200 mg 198-202 mg ±7.5% All 
F4 20 175 mg 172-179 mg ±7.5% All 
F5 20 150 mg 147-152 mg ±7.5% All 
 
Content Uniformity 
10 capsules were evaluated for content uniformity. All the capsules were found to pass the test.  Table 5 shows the details of the 
content uniformity test. 
Table 5: Content uniformity test conducted on sustained release carbopol 971P capsules 
Formula
tion 
No. of capsules Amount of drug 
(theoretical) 
Drug amount 
(Experimental) 
Acceptable Wt. 
variation 
No. of capsules 
passed 
F1 10 50 mg 48-51 mg ±15% All 
F2 10 50 mg 48-52 mg ±15% All 
F3 10 50 mg 49-51 mg ±15% All 
F4 10 50 mg 48-52 mg ±15% All 
F5 10 50 mg 47-51 mg ±15% All 
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CONCLUSION  
Sustained release formulations have been largely used to 
improve the physicochemical and pharmacokinetic 
properties of drugs. A number of polymers for this purpose 
have been used. In the present study carbopol 971P was 
used as rate controlling polymer in the formulation of 
sustained release capsules. From the above study it can be 
concluded that carbopol 971P capsules are efficient in 
providing the sustained release of losartan potassium. The 
hydration and swelling properties of carbopol capsules were 
excellent. The capsules efficiently provided drug release over 
a period of 12 hours with almost a constant rate. The 
capsules also displayed great matrix integrity over the whole 
period of dissolution testing. The above developed carbopol 
971P capsules may prove beneficial in improving the 
pharmacokinetic profile of losartan potassium. The same is 
required to be investigated in further studies. 
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